牛牛AI助理已提取核心訊息
Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.
Ardelyx, Inc., a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, on February 22, 2024. The company reported strong commercial performance with $80.1 million in net product sales revenue from IBSRELA and $2.5 million from XPHOZAH, launched in November 2023. Ardelyx ended the year with $184.3 million in cash and investments. The company expects 2024 net product sales revenue for IBSRELA to be between $140.0 to $150.0 million. Ardelyx also highlighted the approval of tenapanor for hyperphosphatemia in Japan and the initiation of a long-term observational study for XPHOZAH. The company's total revenues for 2023 were $124.5 million, a significant increase from $52.2 million in 2022. Research and development expenses remained stable at $35.5 million, while selling, general and administrative expenses increased to $134.4 million due to commercialization efforts. The net loss for the year was $66.1 million, or $(0.30) per share. Ardelyx will host a conference call to discuss these results and updates.
生物製藥公司Ardelyx, Inc. 於2024年2月22日公佈了截至2023年12月31日的年度財務業績。該公司公佈了強勁的商業業績，IBSRELA的產品淨銷售收入爲8,010萬美元，XPHOZAH於2023年11月推出，淨產品銷售收入爲250萬美元。Ardelyx在年底擁有1.843億美元的現金和投資。該公司預計，IBSRELA2024年的淨產品銷售收入將在1.4億美元至1.5億美元之間。Ardelyx還強調了日本批准tenapanor治療高磷血癥以及XPHOZAH的長期觀察性研究的啓動。該公司2023年的總收入爲1.245億美元，較2022年的5,220萬美元大幅增加。研發費用穩定在3550萬美元，而由於商業化努力，銷售、一般和管理費用增至1.344億美元。該年度的淨虧損爲6,610萬美元，合每股虧損0.30美元。Ardelyx 將主持電話會議，討論這些結果和更新。
生物製藥公司Ardelyx, Inc. 於2024年2月22日公佈了截至2023年12月31日的年度財務業績。該公司公佈了強勁的商業業績，IBSRELA的產品淨銷售收入爲8,010萬美元，XPHOZAH於2023年11月推出，淨產品銷售收入爲250萬美元。Ardelyx在年底擁有1.843億美元的現金和投資。該公司預計，IBSRELA2024年的淨產品銷售收入將在1.4億美元至1.5億美元之間。Ardelyx還強調了日本批准tenapanor治療高磷血癥以及XPHOZAH的長期觀察性研究的啓動。該公司2023年的總收入爲1.245億美元，較2022年的5,220萬美元大幅增加。研發費用穩定在3550萬美元，而由於商業化努力，銷售、一般和管理費用增至1.344億美元。該年度的淨虧損爲6,610萬美元，合每股虧損0.30美元。Ardelyx 將主持電話會議，討論這些結果和更新。
有用
沒用
